# Eikon Therapeutics (EIKN) — Analyst Forecast

EIKN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/eikn/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 5 | 0 | 1 | 6 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 14, 2026 | Wedbush | Maintained | Underperform | $4.00 |
| May 12, 2026 | Wedbush | Maintained | Underperform | $5.00 |
| Mar 31, 2026 | Wedbush | Maintained | Underperform | $7.00 |
| Mar 2, 2026 | B of A Securities | Initiated Coverage | Buy | $34.00 |
| Mar 2, 2026 | JP Morgan | Initiated Coverage | Overweight | $29.00 |
| Mar 2, 2026 | Morgan Stanley | Initiated Coverage | Overweight | $32.00 |
| Mar 2, 2026 | Mizuho | Initiated Coverage | Outperform | $26.00 |
| Mar 2, 2026 | Cantor Fitzgerald | Initiated Coverage | Overweight | — |
| Feb 26, 2026 | Wedbush | Initiated Coverage | Underperform | $7.00 |

## Frequently Asked Questions

### Is EIKN a buy, sell, or hold?

Analysts covering Eikon Therapeutics currently average a Buy rating: 5 buy, 0 hold and 1 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on EIKN?

On Aug 14, 2026, Wedbush maintained Eikon Therapeutics at Underperform with a price target of $4.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).